SCHEMBL5189169

SCHEMBL5189169

Cc1c(Oc2ccc(S(C)(=O)=O)cc2F)ncnc1OC1CCN(c2cc(CC=O)ccn2)CC1

nearest known ligand 0.59

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 20/20 0.59
CYP2C9 P11712 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5188918 0.85 GPR119 (0.64) GPR119CYP2C9
SCHEMBL5189012 0.84 GPR119 (0.58) GPR119CYP2C9
SCHEMBL5046636 0.84 GPR119 (0.59) GPR119CYP2C9
SCHEMBL5188908 0.83 GPR119 (0.58) GPR119CYP2C9
SCHEMBL6364037 0.81 GPR119 (0.63) GPR119CYP2C9
SCHEMBL2406808 0.80 GPR119 (0.62) GPR119CYP2C9
SCHEMBL2403962 0.80 GPR119 (0.66) GPR119CYP2C9
SCHEMBL5048678 0.80 GPR119 (0.62) GPR119CYP2C9
SCHEMBL27769032 0.79 GPR119 (0.65) GPR119CYP2C9
SCHEMBL6363846 0.79 GPR119 (0.65) GPR119CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1758565-A2 COMBINATION THERAPY FOR THE TREATMENT OF DIABETES AND CONDITIONS RELATED THERETO AND FOR THE TREATMENT OF CONDITIONS AMELIORATED BY INCREASING A BLOOD GLP-1 LEVEL Arena Pharmaceuticals, Inc. (US) 2007-03-07 EP disclosed
WO-2006076231-A2 COMBINATION THERAPY FOR THE TREATMENT OF DIABETES AND CONDITIONS RELATED THERETO AND FOR THE TREATMENT OF CONDITIONS AMELIORATED BY INCREASING A BLOOD GLP-1 LEVEL ARENA PHARMACEUTICALS, INC. (US) 2006-07-20 WO disclosed